Cat. #153248
Pr8/22 Cell Line
Cat. #: 153248
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Mouse
Tissue: Lymphatic Tissue
Disease: Cancer
Model: Tumour line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Timothy Ward
Institute: Cancer Research UK Manchester Institute
Tool Details
*FOR RESEARCH USE ONLY
- Name: Pr8/22 Cell Line
- Tool sub type: Continuous
- Parental cell: P388
- Organism: Mouse
- Tissue: Lymphatic Tissue
- Disease: Cancer
- Growth properties: Suspension
- Model: Tumour line
- Conditional: No
- Description: The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm originating in DBA/2 mouse and converted to ascitic form in the first mouse transfer. Pr8/22 is resistant to daunorubicin and is multi drug resistant (MDR). Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged.
- Production details: The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm.
- Cellosaurus id: CVCL_4276
Handling
- Format: Frozen
- Growth medium: Sub-culture routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37?°C. It is recommended to culture the cells without drug upon resuscitation until the first passage.Culture Medium: RPMI 1640 + 2mM Glutamine + 10% Horse Serum (HS); treat once a month with 0.1??M Daunorubicin.
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- McGown et al. 1983. Cancer Chemother Pharmacol. 11(2):113-6. PMID: 6627597.
- Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures.
